Related Experiment Video
Updated: Jan 17, 2026

Simple Continuous Glucose Monitoring in Freely Moving Mice
Published on: February 24, 2023
Use of Continuous Glucose Monitors in Publicly Insured Youth With Type 2 Diabetes: A 12-month Pilot and Feasibility
Sejal Shah1, Molly L Tanenbaum1,2, Alondra Loyola1
1Department of Pediatrics, Division of Pediatric Endocrinology, Stanford University School of Medicine, Stanford, CA, USA.
Background:
Type 2 diabetes (T2D) disproportionately affects youth with public insurance of minority and lower socioeconomic status backgrounds. We aimed to determine feasibility of CGM use in this understudied population.
Methods:
We enrolled youth <20 years old with T2D, provided or prescribed intermittent scanned CGM, and followed established clinic workflows with six data collection visits over 12-months. CGM use was measured by % wear time per two-week period (>75% wear-time as goal) from downloaded report prior to clinic visit. Exploratory outcomes included: 14-day CGM wear time in range (TIR: % time spent between 70 and 180 mg/dl), HbA1c, and patient-reported outcomes (PROs) collected from youth and parents.
Results:
We enrolled 30 youth (age 15.1 years [SD 2.48]; HbA1c 10.2%, range: 6.5%-15.5%), 46.7% female, 90% Hispanic. At baseline, 37% previously used CGM and 53% lacked glucometer data. CGM use was 50% at three months and 23% at 12 months. CGM wear time decreased by 6.4 days per two weeks by 12 months. Mean HbA1c was 9.8% at 12 months and median TIR decreased from 71% to 42%. Parents and youth had moderate-to-positive attitudes about diabetes technology. Youth endorsed fair levels of global health; and youth and parents endorsed fair general and diabetes-related health-related quality of life.
Conclusions:
Strategies for sustained CGM use in youth with T2D may differ from adults with T2D or youth with type 1 diabetes. Additional studies are needed to evaluate facilitators and barriers of sustained CGM use to optimize CGM use in youth with T2D.
Clinicaltrials:
gov registration:NCT05074667.
Related Concept Videos
Diabetes Mellitus: Type 2 and Gestational
Diabetes Mellitus: Overview and Type I Subtype
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Diabetes: Symptoms, Diagnosis, and Complications
Diabetes: Management and Pharmacotherapy
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Glucose Homeostasis: Regulation of Blood Glucose
During fasting, when blood glucose levels are low, the pancreas secretes glucagon. it...

